Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide

References

• Banik N, Hussain A, Ramteke A, Sharma H, Maji T. 2012. Preparation and evaluation of the effect of particle size on the properties of chitosan-montmorillonite nanoparticles loaded with isoniazid. RSC Adv. 2(28):10519–10528.
   Web of Science ®Google Scholar
• Changsan N, Chan HK, Separovic F, Srichana T. 2009. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci. 98(2):628–639.
   PubMed Web of Science ®Google Scholar
• Debnath SK, Saisivam S, Debanth M, Omri A. 2018. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide. PLoS One. 13(1):e0190976–12.
   PubMed Web of Science ®Google Scholar
• Hassani S, Laouini A, Fessi H, Charcosset C. 2015. Preparation of chitosan-TPP nanoparticles using microengineered membranes-Effect of parameters and encapsulation of tacrine. Colloids Surf A Physicochem Eng Asp. 482:34–43.
   Web of Science ®Google Scholar
• Kim J-J, Lee H-M, Shin D-M, Kim W, Yuk J-M, Jin HS, Lee S-H, Cha G-H, Kim J-M, Lee Z-W, et al. 2012. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe. 11(5):457–468.
   PubMed Web of Science ®Google Scholar
• Kolloli A, Subbian S. 2017. Host-directed therapeutic strategies for tuberculosis. Front Med (Lausanne)). 4:171–114.
   PubMed Web of Science ®Google Scholar
• Kurz S, Furin J, Bark C. 2016. Drug resistance TB: Challenges and Progress. Infect Dis Clin North Am. 30(2):509–522.
   PubMed Web of Science ®Google Scholar
• Milligan KA, Winstead C, Smith J. 2018. Preparation and physicochemical characterization of chitosan nanoparticles for controlled delivery of oxytocin. Int J Pharm Sci Res. 9(4):1430–1440.
   Web of Science ®Google Scholar
• Miranda MS, Rodrigues M, Domingues R, Torrado E, Reis R, Pedrosa J, Gomes M. 2018. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery. Mater Sci Eng C Mater Biol Appl. 93:1090–1103.
   PubMed Web of Science ®Google Scholar
• Nakahira K, Porras MA, Choi A. 2016. Autophagy in pulmonary diseases. Am J Respir Crit Care Med. 194(10):1196–1207.
   PubMed Web of Science ®Google Scholar
• Parumasivam T, Chang R, Abdelghany S, Ye T, Britton WJ, Chan HK. 2016. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 102:83–101.
   PubMed Web of Science ®Google Scholar
• Pascual P, Carrillo G, Hontanon A, Martinez P. 2018. Treatment of pulmonary and extrapulmonary tuberculosis. Enferm Infecc Microbiol Clin (English ed.). 36:507–516.
   PubMed Web of Science ®Google Scholar
• Peng T, Lin S, Niu B, Wang X, Huang Y, Zhang X, Li G, Pan X, Wu C. 2016. Influence of physical properties of carrier on the performance of dry powder inhalers. Acta Pharm Sin B. 6(4):308–318.
   PubMed Web of Science ®Google Scholar
• Pham D-D, Fattal E, Tsapis N. 2015. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm. 478(2):517–529.
   PubMed Web of Science ®Google Scholar
• Poggi M, Barroso R, Costa-Filho A, Barbosa H, Heloisa BB, Pavan F, Leite CQ, Gambino D, Torre MH. 2013. New Isoniazid Complexes, Promising Agents Against Mycobacterium tuberculosis. J Mex Chem Soc. 57(3):198–204.
   Web of Science ®Google Scholar
• Punturee K, Wild CP, Vinitketkumneun U. 2004. Thai medicinal plants modulate nitric oxide and tumor necrosis factor-alpha in J774.2 mouse macrophages. J Ethnopharmacol. 95(2-3):183–189.
   PubMed Web of Science ®Google Scholar
• Rasul RM, Tamilarasi Muniandy M, Zakaria Z, Shah K, Chee CF, Dabbagh A, Rahman NA, Wong TW. 2020. A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers. Carbohydr Polym. 250:116800.
   PubMed Web of Science ®Google Scholar
• Rawal T, Patel S, Butani S. 2018. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline. Eur J Pharm Sci. 124:273–287.
   PubMed Web of Science ®Google Scholar
• Rojanarat W, Changsan N, Tawithong E, Pinsuwan S, Chan H-K, Srichana T. 2011. Isoniazid Proliposome Powders for Inhalation-Preparation, Characterization and Cell Culture Studies. IJMS. 12(7):4414–4434.
   Google Scholar
• Seung KJ, Keshavjee S, Rich ML. 2015. Multidrug-resistant tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 5(9):a017863.
   PubMed Web of Science ®Google Scholar
• Sharma V, Kalonia D. 2004. Effect of vacuum drying on protein-mannitol interactions: The physical state of mannitol and protein structure in the dried state. AAPS PharmSciTech. 5(1):58–12.
   Web of Science ®Google Scholar
• Srichana T, Suedee R, Srisudjai P. 2003. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie. 58(2):125–129.
   PubMed Web of Science ®Google Scholar
• Thanwar M, Dwivedi D, Gharia AK. 2014. The fundamental characteristics of pyrazinamide: A review. J Chem Sci. 4(2):110–113.
   Google Scholar
• World Health Organization [WHO]. 2019. Global tuberculosis report 2019-fact sheet. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Torrado S, Torrado S. 2002. Characterization of physical state of mannitol after freeze-drying: effect of acetylsalicylic acid as a second crystalline cosolute. Chem Pharm Bull (Tokyo)). 50(5):567–570.
   PubMed Web of Science ®Google Scholar
• Tsai W-H, Yu K-H, Huang Y-C, Lee C-I. 2018. EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles. Int J Nanomed. 13:903–916.
   PubMed Web of Science ®Google Scholar
• Zhai W, Wu F, Zhang Y, Fu Y, Liu Z. 2019. The immune escape mechanisms of Mycobacterium tuberculosis. Int J Mol Sci. 20(340):1–18.
   Google Scholar